Toward a More Proactive Health Care System
Dr. Alexandra Bause explains how today’s reactive approach provides sick care, not health care—and how biopharma strives to change that.
Dr. Alexandra Bause explains how today’s reactive approach provides sick care, not health care—and how biopharma strives to change that.
Biopharma companies can promote the success of product launches by initiating cross-functional collaboration on evidence generation early in the development process.
The Team B approach involves assembling an independent cross-functional team to conduct rapid reviews of launch plans and market conditions for new pharmaceutical products.
Biopharma and medtech companies that adopt a digital-native approach can generate better outcomes, lower costs, and greater customer satisfaction.
Gene therapy, stem cells, and other advances are changing the way complex diseases are treated. To capitalize, biopharma and biotech companies need to make strategic decisions about where to focus their efforts.
Chief Commercial Officer Everett Cunningham describes Exact Sciences’ efforts to boost awareness of this deadly disease.
Lessons learned during COVID-19 present an opportunity to improve the US public health system. Expanding practitioners’ capacities in decision-making, communication, and working with data is a critical step.
The finances of the US health system are weak. If systemic issues are not resolved, the situation will worsen, with detrimental consequences for patient care and care equity.
A confluence of factors means the time-tested approaches to cost control won’t work. Insurers need to rethink how they achieve more with less while maintaining a strong customer focus and employee value proposition.
A new regulation makes detailed pricing data widely available for the first time. Providers and insurers need to prepare now for a changed competitive playing field.
The technology has a range of uses in medtech, and the main challenge is knowing how and where to start. Here are 60 ways to generate quick wins.
Medical technology companies play a big part in health care’s carbon emissions problem, both at the patient and provider levels. Fortunately, these firms can reduce their footprint affordably.
Here’s what to keep in mind when developing and commercializing software as a medical device.
A sea change is underway in how companies win regulatory approval for new health care products—particularly in the use of digital technology—and which markets they prioritize.
COVID-19 offered valuable lessons in combating epidemic-level disease. Four measures can help institutionalize what we’ve learned.
BCG Executive Perspectives offer insights on global topics that matter most to leaders in the public and private sectors. Explore these topics and read the latest thinking from BCG's experts below.
What has worked, what can be improved, and what needs to be reimagined so that we are better prepared for the next pandemic and better able to improve health in the world’s poorest nations?
Experts across BCG and BCG X talk about the trends and opportunities that lie ahead for the digital health care market.